HomeAI · summaries
Storia in 2 fonti
CellCentric raises $220M for a ‘transformative’ multiple myeloma medicine
A Series D round led by Venrock will support an ongoing Phase 2 study, and planned Phase 3 trial, of an oral drug the biotech sees as a differentiated option for patients with persistent disease.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
CellCentric raises $220M for a ‘transformative’ multiple myeloma medicine
A Series D round led by Venrock will support an ongoing Phase 2 study, and planned Phase 3 trial, of an oral drug the biotech sees as a differentiated option for patients with…
- ·
endpoints.news
CellCentric raises $220M to get multiple myeloma pill to market
CellCentric has reeled in a $220 million Series D to help it address multiple myeloma patients who have exhausted all other treatment options.